What are your top takeaways in Myeloma from ASH 2025?  

As is probably true for most multiple myeloma-focused investigators, my interest was most piqued by the results of the MajesTEC-3 trial, which demonstrated an 83% 3-year progression-free survival in a population of patients with relapsed or refractory disease resulting from teclistamab and daratumum...

The most clinically impactful MM studies in 2026 would be MajesTEC-3 RediecTT LimiTec

The top abstract undoubtedly was the Phase III MajesTEC-3 trial presented by Dr. Marivi Mateos, which demonstrated significant PFS and OS benefits with teclistamab & daratumumab (tec-dara) versus standard regimens in relapsed myeloma. Once this is approved, decision-making around BCMA CAR-T ve...

The presentation that will likely have the most immediate and far-reaching consequences would be MajesTEC-3. What was so noteworthy was the incredibly high response, depth of response, and durability. Many colleagues seem eager for the opportunity to use this combination. We will have to see if...

The use of teclistamab + dara (MajesTEC-3 results) compared to DVD or DPD is very promising in first-line relapsed MM patients who are not candidates for CAR-T cells. COBRA study - use of carfilzomib in high-risk MM seems very promising, though the comparator arm only had velcade use for 32 weeks...

1: Publication Number: 696 - Abstract Title: First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201. After daratumumab/bortezomib/cyclophosphamide/dexamethasone as first-line treatment, other regimens such as lenalidomid...

LBA-6 (MajesTEC-3): PFS and OS data were, of course, extremely impressive. This combination (teclistamab+daratumumab) will be a true competitor to cilta-cel in the lenalidomide-refractory, PI-exposed, population. This study shows the power of Tec-Dara, and while the change in practice to use of da...

The late-breaking abstracts were the best. The in vivo gene therapy presentation could be practice-changing in delivering anti-BCMA T cells. The final one on teclistimab/Dara for myeloma was also significant.

MAJESTIC-3 studyIn vivo CAR-TAnito-celNone has immediate practice-changing potential.They could be practice-changing in the future. No immediate impact.

1. MajesTEC-3 This late-breaking abstract was the obvious top ASH highlight for most myeloma physicians, and for several good reasons. First, the relatively flat, almost Hodgkin lymphoma-esque progression-free survival (PFS) curve, reflecting an 83% 3-year PFS, is not something myeloma physicia...